Endothelin-converting enzyme-1 activity, endothelin-1 production, and free radical-dependent vasoconstriction in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 36, Issue 3, 2013, Pages 577-587

  Palmer, Jennifer C ^a   Tayler, Hannah M ^a   Love, Seth ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; cerebral blood flow; endothelin 1; free radicals; vascular dysfunction

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; FREE RADICAL; MESSENGER RNA; SUPEROXIDE DISMUTASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN BLOOD FLOW; BRAIN CELL; CELL LYSATE; CEREBRAL VASOCONSTRICTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MICROVASCULAR ENDOTHELIAL CELL; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; TEMPORAL CORTEX; VASOCONSTRICTION;

EID: 84881453206     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130383     Document Type: Article

References (69)

1. Imran MB,Kawashima R,Awata S, Sato K, Kinomura S, Ono S, Sato M, Fukuda H (1999) Tc-99m HMPAO SPECT in the evaluation of Alzheimer's disease: Correlation between neuropsychiatric evaluation andCBFimages. J Neurol Neurosurg Psychiatry 66, 228-232
2. Mak HK, Chan Q, Zhang Z, Petersen ET, Qiu D, Zhang L, Yau KK, Chu LW, Golay X (2012) Quantitative assessment of cerebral hemodynamic parameters by QUASAR arterial spin labeling in Alzheimer's disease and cognitively normal elderly adults at 3-Tesla. J Alzheimers Dis 31, 33-44
3. Dekosky ST, Shih WJ, Schmitt FA, Coupal J, Kirkpatrick C (1990) Assessing utility of single photon emission computed tomography spect scan in Alzheimer disease correlation with cognitive severity. Alzheimer Dis Assoc Disord 4, 14-23
4. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: Initial experience. Radiology 234, 851-859
5. Ruitenberg A, den Heijer T, Bakker SLM, van Swieten JC, Koudstaal PJ, Hofman A, Breteler MMB (2005) Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam study. Ann Neurol 57, 789-794
6. Chao LL, Buckley ST, Kornak J, Schuff N,Madison C, Yaffe K, Miller BL, Kramer JH,WeinerMW(2010) ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis Assoc Disord 24, 19-27
7. Dickstein DL, Walsh J, Brautigam H, Stockton SD, Gandy S, Hof PR (2010) Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 77, 82-102
8. de la Torre JC (2005) Is Alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion? Ann Neurol 57, 783-784
9. Brun A, Englund E (1986) A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann Neurol 19, 253-262
10. Englund E, Brun A, Alling C (1988) White matter changes in dementia of Alzheimer's type. Biochemical and neuropathological correlates. Brain 111, 1425-1439
11. Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, Miklossy J (2002) Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 33, 1986-1992
12. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5, 347-360
13. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C (2002) Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 9, 61-68
14. Niwa K, Carlson GA, Iadecola C (2000) Exogenous A β40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 20, 1659-1668
15. Naidoo V, Naidoo S, Raidoo DM (2004) Immunolocalisation of endothelin-1 in human brain. J Chem Neuroanat 27, 193-200
16. Palmer JC, Barker R, Kehoe PG, Love S (2012) Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-beta. J Alzheimers Dis 29, 853-861
17. Giaid A, Gibson SJ, Herrero MT, Gentleman S, Legon S, Yanagisawa M, Masaki T, Ibrahim NBN, Roberts GW, Rossi ML, Polak JM (1991) Topographical localization of endothelin messenger-RNA and peptide immunoreactivity in neurons of the human brain. Histochemistry 95, 303-314
18. Lee ME, Delamonte SM, Ng SC, Bloch KD, Quertermous T (1990) Expression of the potent vasoconstrictor endothelin in the human central-nervous-system. J Clin Invest 86, 141-147
19. Dashwood MR, Loesch A (2010) Endothelin-1 as a neuropeptide: Neurotransmitter or neurovascular effects? J Cell Commun Signal 4, 51-62
20. Blais V, Fugere M, Denault JB, Klarskov K, Day R, Leduc R (2002) Processing of proendothelin-1 by members of the subtilisin-like pro-protein convertase family. FEBS Lett 524, 43-48
21. Palmer JC, Kehoe PG, Love S (2010) Endothelin-converting enzyme-1 in Alzheimer's disease and vascular dementia. Neuropathol Appl Neurobiol 36, 487-497
22. Palmer JC, Baig S, Kehoe PG, Love S (2009) Endothelinconverting enzyme-2 is increased in Alzheimer's disease and up-regulated by Aβ. Am J Pathol 175, 262-270
23. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB (2003) Alzheimer's disease β-Amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 278, 2081-2084
24. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C (2001) Aβ-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 281, H2417-H2424
25. Palmer JC, Love S (2011) Endothelin receptor antagonists: Potential in Alzheimer's disease. Pharmacol Res 63, 525-531
26. Gentile MT, Vecchione C, Maffei A, Aretini A, Marino G, Poulet R, Capobianco L, Selvetella G, Lembo G (2004) Mechanisms of soluble β-Amyloid impairment of endothelial function. J Biol Chem 279, 48135-48142
27. Dietrich H, Xiang C, Han B, Zipfel G, Holtzman D (2010) Soluble amyloid-, effect on cerebral arteriolar regulation and vascular cells. Mol Neurodegener 5, 15
28. Crawford F, Suo ZM, Fang CH, Mullan M (1998) Characteristics of the in vitro vasoactivity of β-Amyloid peptides. Exp Neurol 150, 159-168
29. Price JM, Sutton ET, Hellermann A, Thomas T (1997) β-Amyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res 19, 534-538
30. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168-171
31. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239-259
32. (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18, S1-2
33. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol (Berl) 123, 1-11
34. Miners JS, Verbeek MM, Rikkert MO, Kehoe PG, Love S (2008) Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods 167, 229-236
35. Miners JS, Kehoe PG, Love S (2008) Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates. J Neurosci Methods 169, 177-181
36. van Helmond Z, Heesom K, Love S (2009) Characterisation of two antibodies to oligomeric Aβ and their use in ELISAs on human brain tissue homogenates. J Neurosci Methods 176, 206-212
37. Iadecola C, Zhang FY, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA (1999)SOD1rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2, 157-161
38. MacLeod KJ, Husain RD, Gage DA, Ahn K (2002) Constitutive phosphorylation of human endothelin-converting enzyme-1 isoforms. J Biol Chem 277, 46355-46363
39. Smith AI, Lew RA, Thomas WG, Tochon-Danguy N (2006) Protein kinase C regulates the cell surface activity of endothelin-converting enzyme-1. Int J Pept Res Ther 12, 291-295
40. Choi DS,Wang D, Yu GQ, Kharazia VN, Chang WS, Mucke L, Messing RO (2006) Protein kinase C epsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Acta Pharmacol Sin 27, 372-372
41. Naomi S, Iwaoka T, Disashi T, Inoue J, KanesakaY, Tokunaga H, Tomita K (1998) Endothelin-1 inhibits endothelinconverting enzyme-1 expression in cultured rat pulmonary endothelial cells. Circulation 97, 234-236
42. Minami M, Kimura M, Iwamoto N, AraiH(1995) Endothelin-1-like immunoreactivity in cerebral-cortex of Alzheimer-type dementia. Prog Neuropsychopharmacol Biol Psychiatry 19, 509-513
43. Luo JH, Grammas P (2010) Endothelin-1 is elevated in Alzheimer's disease brain microvessels and is neuroprotective. J Alzheimers Dis 21, 887-896
44. Deane R, Yan SD, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913
45. Tong XK, Nicolakakis N, Kocharyan A, Hamel E (2005) Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J Neurosci 25, 11165-11174
46. Edvinsson L (2009) Cerebrovascular endothelin receptor upregulation in cerebral ischemia. Curr Vasc Pharmacol 7, 26-33
47. Sun X, He G, Qing H, ZhouW, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W (2006) Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 103, 18727-18732
48. Zhang X, Zhou K,Wang RS, Cui JK, Lipton SA, Liao FF, Xu HX, Zhang YW (2007) Hypoxia-inducible factor 1 α (HIF 1 α)-mediated hypoxia increases BACE1 expression and β-Amyloid generation. J Biol Chem 282, 10873-10880
49. Bourasset F, Ouellett M, Tremblay C, Julien C, Do TM, Oddo S, LaFerla F, Calon F (2009) Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. Neuropharmacology 56, 808-813
50. Tong XK, Nicolakakis N, Fernandes P, Ongali B, Brouillette J, Quirion R, Hamel E (2009) Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol Dis 35, 406-414
51. Park L, Anrather J, Forster C, Kazama K, Carlson GA, Iadecola C (2004) Aβ-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab 24, 334-342
52. McLellan ME, Kajdasz ST, Hyman BT, Bacskai BJ (2003) In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci 23, 2212-2217
53. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S,Wei Y, Ayata C, Frosch MP, Greenberg SM, Bacskai BJ (2011) Cerebrovascular lesions induce transient β-Amyloid deposition. Brain 134, 3697-3707
54. Miners JS, Ashby EL, Baig S, Harrison R, Tayler H, Speedy E, Prince JA, Love S, Kehoe PG (2009) Angiotensin-converting enzyme levels and activity in Alzheimer's disease: Differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 1, 163-177
55. Zheng WH, Bastianetto S, Mennicken F, MaW, Kar S (2002) Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 115, 201-211
56. Murray IVJ, Sindoni ME, Axelsen PH (2005) Promotion of oxidative lipid membrane damage by amyloid beta proteins. Biochemistry (Mosc) 44, 12606-12613
57. Biesold D, Inanami O, Sato A, Sato Y (1989) Stimulation of the nucleus basalis of meynert increases cerebral cortical blood-flow in rats. Neurosci Lett 98, 39-44
58. Pearson HA, Peers C (2006) Physiological roles for amyloid-β peptides. J Physiol 575, 5-10
59. van Helmond Z, Miners JS, Kehoe PG, Love S (2010) Higher soluble amyloid β concentration in frontal cortex of young adults than in normal elderly or Alzheimer's disease. Brain Pathol 20, 787-793
60. Papadopoulos P, Ongali B, Hamel E (2010) Selective in vivo antagonism of endothelin receptors in transforming growth factor-beta 1 transgenic mice that mimic the vascular pathology of Alzheimer's disease. Can J Physiol Pharmacol 88, 652-660
61. Wenzel RR, Fleisch M, ShawS, Noll G, Kaufmann U, Schmitt R, Jones CR, Clozel M, Meier B, Luscher TF (1998) Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 98, 2235-2240
62. Givertz MM, Colucci WS, LeJemtel TH, Gottlieb SS, Hare JM, Slawsky MT, Leier CV, Loh E, Nicklas JM, Lewis BE, Study I (2000) Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 101, 2922-2927
63. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial.[see comment]. Lancet 371, 2093-2100
64. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S (1995) Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79, 2122-2131
65. KatoT, Kassab S,Wilkins FC, Kirchner KA,Keiser J, Granger JP (1995) Endothelin antagonists improve renal-function in spontaneously hypertensive rats. Hypertension 25, 883-887
66. Kohan DE (2010) Endothelin, hypertension and chronic kidney disease: New insights. Curr Opin Nephrol Hypertens 19, 134-139
67. Ohlstein EH, Douglas SA, Ezekiel M, Gellai M (1993) Antihypertensive effects of the endothelin receptor antagonist BQ-123 in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 22, S321-S324
68. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, Weber C, Macdonald PS (2000) Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 102, 411-418
69. Elesber AA, Bonetti PO,Woodrum JE, Zhu XY, Lerman LO, Younkin SG, Lerman A (2006) Bosentan preserves endothelial function in mice overexpressing APP. Neurobiol Aging 27, 446-450